Multiple myeloma: open trials in Greece

40 open trials have a site in Greece. Registry data; only the trial team decides who can take part.

NCT05137054
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Trial Treatment · Phase 1 · Regeneron Pharmaceuticals
Evaggelismos Hospital, Athens · Alexandra Hospital, Athens
Registry updated 2026-11-05
NCT07455851
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 1/2 · Regeneron Pharmaceuticals
Evaggelismos Hospital, Athens · General Hospital of Athens - Alexandra, Athens
Registry updated 2026-11-05
NCT06189833
A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS
Trial Treatment · Phase 2 · European Myeloma Network B.V.
University General Hospital of Alexandroupoli, Alexandroupoli · General Hospital of Athens - Alexandra, Athens · Saint Savvas Oncology Hospital, Athens · Theageneio Cancer Hospital, Thessaloniki
Registry updated 2026-11-04
NCT07222761
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
University General Hospital of Alexandroupoli, Alexandroupoli · Evangelismos S A, Athens · General Hospital of Athens - Alexandra, Athens · University General Hospital of Ioannina, Ioannina · Olympion Therapeftirio General Clinic Of Patras S.A., Patra · Theageneio Cancer Hospital, Thessaloniki
Registry updated 2026-11-04
NCT07393282
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
General Hospital of Athens - Alexandra, Athens · Evangelismos S A, Athens · Olympion General Clinic Patras P.C., Patras · Geniko Nosokomeio Thessalonikis George Papanikolaou, Thessaloniki
Registry updated 2026-11-04
NCT05552222
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
General Hospital of Athens - Alexandra, Athens · Theageneio Cancer Hospital, Thessaloniki · Geniko Nosokomeio Thessalonikis George Papanikolaou, Thessaloniki
Registry updated 2026-11-03
NCT07258511
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Evangelismos S A, Athens · General Hospital of Athens - Alexandra, Athens · Theageneio Cancer Hospital, Thessaloniki · Geniko Nosokomeio Thessalonikis George Papanikolaou, Thessaloniki
Registry updated 2026-11-03
NCT07589634
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 2 · Janssen Research & Development, LLC
Uni General Hospital of Alexandroupolis, Alexandroupoli · Alexandra General Hospital of Athens, Athens · 251 Air Force General Hospital, Athens · Metaxa Cancer Center Hospital Of Piraeus, Piraeus · General University Hospital of Patras, Rio · Hippokration Hospital, Thessaloniki · Theageneio Cancer Hospital, Thessaloniki
Registry updated 2026-11-03
NCT07665450
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Uni General Hospital of Alexandroupolis, Alexandroupoli · Evangelismos S A, Athens · Alexandra General Hospital of Athens, Athens · Laiko General Hospital of Athens, Athens · Theageneio Cancer Hospital, Thessaloniki · Geniko Nosokomeio Thessalonikis George Papanikolaou, Thessaloniki
Registry updated 2026-11-03
NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Celgene
Athens · Athens · G. Papanikolaou General Hospital, Thessaloniki
Registry updated 2026-10-30
NCT04414475
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Trial Treatment · Phase 2 · Karyopharm Therapeutics Inc
Evangelismos S A, Athens · Alexandra Hospital, Athens · Theageneio Cancer Hospital, Thessaloniki
Registry updated 2026-10-29
NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Trial Treatment · Phase 3 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Evaggelismos Hospital, Athens · University General Hospital Attikon, Athens · General University Hospital Of Patras, Patras
Registry updated 2026-10-29
NCT05623020
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Trial Treatment · Phase 3 · Pfizer
Evaggelismos Hospital, Athens · Alexandra Hospital, Athens · University General Hospital of Ioannina, Ioannina · Theageneio Cancer Hospital, Thessaloniki
Registry updated 2026-10-27
NCT04973605
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Trial Treatment · Phase 1/2 · BeOne Medicines
University General Hospital of Alexandroupoli, Alexandroupoli · Alexandra Hospital, Athens
Registry updated 2026-10-26
2025-523815-12-00
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Cilag International
General Hospital of Athens - Alexandra, Athens · Evangelismos S A, Athens · University General Hospital "ATTIKON" - General Hospital of West Attica "H AGIA VARVARA", Chaïdári · University General Hospital of Ioannina, Ioannina
Registry updated 2026-10-19
NCT05669989
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Trial Treatment · Phase 2 · Sanofi
Athens · Athens · Pátrai
Registry updated 2026-10-15
NCT05735704
Early Detection and Screening of Hematological Malignancies - SANGUINE
Research · JaxBio Ltd
National and Kapodistrian University of Athens (NKUA), Athens
Registry updated 2026-10-15
2026-526654-14-01
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Trial Treatment · Phase 3 · Janssen Cilag International
University General Hospital of Alexandroupoli, Alexandroupoli · General Hospital of Athens - Alexandra, Athens · Laiko General Hospital of Athens, Athens · Evangelismos S A, Athens · Theageneio Cancer Hospital, Thessaloniki · Geniko Nosokomeio Thessalonikis George Papanikolaou, Thessaloniki
Registry updated 2026-10-14
NCT04643002
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Trial Treatment · Phase 1/2 · Sanofi
Athens · Athens
Registry updated 2026-10-13
NCT06980480
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Trial Treatment · Phase 3 · Takeda
Alexandra Hospital, Athens · University General Hospital of Ioannina, Ioannina
Registry updated 2026-10-13
NCT07555938
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Trial Treatment · Phase 3 · Hoffmann-La Roche
General Hospital of Athens - Alexandra, Athens · Evaggelismos Hospital, Athens · Theageneio Cancer Hospital, Thessaloniki
Registry updated 2026-10-13
NCT05243797
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Trial Treatment · Phase 3 · European Myeloma Network B.V.
University General Hospital of Alexandroupoli, Alexandroupoli · Alexandra Hospital, Athens · Evaggelismos Hospital, Athens · Theageneio Cancer Hospital, Thessaloniki
Registry updated 2026-10-07
NCT07518186
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
University General Hospital Attikon General Hospital Of West Attica H Agia Varvara, Athens · Alexandra General Hospital of Athens, Athens · Evangelismos S A, Athens · University General Hospital of Ioannina, Ioannina
Registry updated 2026-09-25
2025-524793-42-00
Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 2 · Janssen Cilag International
University General Hospital of Alexandroupoli, Alexandroupoli · 251 Air Force General Hospital, Athens · General Hospital of Athens - Alexandra, Athens · General University Hospital Of Patras, Patras · Metaxa Cancer Center Hospital Of Piraeus, Pireas · Theageneio Cancer Hospital, Thessaloniki · Hippokration Hospital, Thessaloniki
Registry updated 2026-09-11
NCT06988488
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Trial Treatment · Phase 1/2 · Celgene
Evaggelismos Hospital, Athens · Alexandra Hospital, Athens
Registry updated 2026-09-02

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error